Elacridar, an ABCB1 modulator acting as a drug transporter, has been proven to have beneficial effects on the resistance of cancer cells to standard chemotherapeutic agents. This unique delivery system makes resistant cancers more susceptible to standard chemotherapeutic regimen. A study done by Ho Lun Wong et al showed beneficial results when Elacridar was used[…]
Elacridar – A Unique Delivery System Fighting Chemotherapy Resistance
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: cancer treatmentchemotherapyDocetaxelimatinibIrinotecanPaclitaxel Jun 03, 2011
Adalimumab sustains clinical remission after 2 years of therapy in Crohn’s disease
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: AdalimumabHumira May 27, 2011
Studies with Adalimumab and a TNF-α blockade shows promising results for Adalimumab therapy for joint pain. Joint pains have inflicted thousands of people worldwide. Age is a non-modifiable risk factor when it comes to degenerative bone disease. However, certain autoimmune joint diseases affect the young population as well. Juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis[…]
LGM Pharma responds to soaring Potassium Iodide demands in the US amidst fears of radiation contamination in Japan and West Coast
Anti-Fungal, Drug Research & Development API May 17, 2011
For several years now, LGM Pharma has been a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged a longstanding partnership with GlaxoSmithKline, Eli[…]
Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer
Monoclonal Antibodies / mAb Tags: 180288-69-1chemotherapyHER2-positiveHerceptinTrastuzumab May 16, 2011
A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]
Levocloperastine Fendizoate: The Better Antitussive Agent Over Codeine
Drug Research & Development API May 05, 2011
Many of the antitussive agents available in the market today act on the CNS, and cause the adverse events mostly associated with them such as sedation, vomiting, and nausea. One in particular, codeine, can lead to drug dependence. Because of this, pharmaceutical companies were prompted to develop a peripherally-acting antitussive agent that minimizes these central[…]
Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)
Antidepressant, Drug Research & Development API, FDA Approved 2011 Tags: Major Depressive DisorderserotoninSSRI May 02, 2011
Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year. The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood.[…]
Bazedoxifene Proven Safe and Effective For Women At Risk For Osteoporosis
Drug Research & Development API, Hormonal Agent, Osteoporosis Tags: European Commissionosteoporosis May 02, 2011
A clinical study spanning two years investigated the effects of the drug Bazedoxifene (Conbriza) at 10, 20 and 40 mg on postmenopausal women at risk for osteoporosis. The results showed positive indications for preventing bone loss and reducing bone turnover. What’s more is that the study demonstrated the drug’s safety profile and its use is[…]
Antiangiogenic Agents – Providing an Alternative Approach
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic Tags: 114977-28-5BevacizumabDocetaxelWHO May 02, 2011
A recent study conducted by the Queens University Belfasts School of Pharmacy revealed the ability of the recombinant protein FKBPL to inhibit tumor growth by disrupting the blood supply to these tumors. This method of cancer treatment called neovascularization is certainly not new with several agents exhibiting the same mode of action already available in[…]
Immunosuppressive Drugs for Transplant – Treatments, Side Effects, and Future Research & Development
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6EverolimusFingolimod HydrochlorideImmunosuppressantLenalidomideMethotrexateSirolimus Mar 15, 2011
For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]
Monoclonal Antibodies (mAbs) – Growth, Supply, and Uses for Cancer Treatment
Antithrombotic, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1331731-18-1AdalimumabAlemtuzumabBevacizumabchemotherapyEGFRRituximabTrastuzumab Feb 11, 2011
What Are Monoclonal Antibodies? A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders. Growing Interest for Monoclonal Antibody Therapies Monoclonal antibodies were initially[…]